Discovery of dual function acridones as a new antimalarial chemotype

Nature

Volumn 459, Issue 7244, 2009, Pages 270-273

  Kelly, Jane X ^a,b   Smilkstein, Martin J ^a,b,c,f   Brun, Reto ^d   Wittlin, Sergio ^d   Cooper, Roland A ^e   Lane, Kristin D ^e,g   Janowsky, Aaron ^a,c   Johnson, Robert A ^a,c   Dodean, Rozalia A ^a,b   Winter, Rolf ^a,b   Hinrichs, David J ^a,c   Riscoe, Michael K ^a,b,c  

^a PORTLAND VA MEDICAL CENTER   (United States)

^b PORTLAND STATE UNIVERSITY   (United States)

^c OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^d SWISS TROPICAL AND PUBLIC HEALTH INSTITUTE   (Switzerland)

^e OLD DOMINION UNIVERSITY   (United States)

^f Oregon Translational Research and Drug Development Institute   (United States)

^g VIRGINIA COMMONWEALTH UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

3 CHLORO 6 (2 DIETHYLAMINO ETHOXY) 10 (2 DIETHYLAMINO ETHYL) ACRIDONE; ACRIDONE DERIVATIVE; AMODIAQUINE; ANTIMALARIAL AGENT; CHLOROQUINE; HEMATIN; HEME; MEFLOQUINE; PIPERAQUINE; QUININE; T 3 5; UNCLASSIFIED DRUG; VERAPAMIL;

ANTIBIOTICS; ANTIMALARIAL AGENT; CHEMOTHERAPY; COAL TAR; DETOXIFICATION; DISEASE TREATMENT; DRUG DEVELOPMENT; DRUG RESISTANCE; EMERGENCE; INNOVATION; MALARIA; SURVIVAL;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIMALARIAL ACTIVITY; ANTIMALARIAL DRUG RESISTANCE; ARTICLE; BEHAVIOR CHANGE; CHEMOSENSITIZATION; COMBINATION CHEMOTHERAPY; DOSE RESPONSE; DRUG CYTOTOXICITY; DRUG EFFICACY; DRUG MEGADOSE; DRUG POTENCY; DRUG POTENTIATION; DRUG SENSITIZATION; DRUG SYNTHESIS; ERYTHROCYTE; HUMAN; HUMAN CELL; IC 50; IN VITRO STUDY; IN VIVO STUDY; LYMPHOCYTE PROLIFERATION; MONOTHERAPY; MOUSE; MULTIDRUG RESISTANCE; NONHUMAN; PH; PHYSICAL CHEMISTRY; PLASMODIUM BERGHEI INFECTION; PLASMODIUM FALCIPARUM; PLASMODIUM YOELII INFECTION; PRIORITY JOURNAL; SKIN FIBROBLAST; SPLEEN LYMPHOCYTE;

ACRIDONES; ANIMALS; ANTIMALARIALS; DRUG DISCOVERY; DRUG RESISTANCE; DRUG SYNERGISM; HEME; MEMBRANE TRANSPORT PROTEINS; MUTATION; PLASMODIUM FALCIPARUM; PLASMODIUM YOELII; PROTOZOAN PROTEINS; QUININE; QUINOLINES; TROPHOZOITES; VERAPAMIL;

PLASMODIUM FALCIPARUM;

EID: 67349189204     PISSN: 00280836     EISSN: 14764687     Source Type: Journal    
DOI: 10.1038/nature07937     Document Type: Article

References (28)

1. Yayon, A., Cabantchik, Z. I. & Ginsburg, H. Identification of the acidic compartment of Plasmodium falciparum-infected human erythrocytes as the target of the antimalarial drug chloroquine. EMBO J. 3, 2695-2700 (1984).
2. Olliaro, P. L. & Goldberg, D. E. The Plasmodium digestive vacuole: metabolic headquarters and choice drug target. Parasitol. Today 11, 294-297 (1995).
3. Sullivan, D. J. Jr, Gluzman, I. Y., Russell, D. G. & Goldberg, D. E. On the molecular mechanism of chloroquine's antimalarial action. Proc. Natl Acad. Sci. USA 93, 11865-11870 (1996).
4. Wellems, T. E. Plasmodium chloroquine resistance and the search for a replacement antimalarial drug. Science 298, 124-126 (2002).
5. Kumar, S., Guha, M., Choubey, V., Maity, P. & Bandyopadhyay, U. Antimalarial drugs inhibiting hemozoin (β-hematin) formation: a mechanistic update. Life Sci. 80, 813-828 (2007).
6. Krugliak, M., Zhang, J. & Ginsburg, H. Intraerythrocytic Plasmodium falciparum utilizes only a fraction of the amino acids derived from the digestion of host cell cytosol for the biosynthesis of its proteins. Mol. Biochem. Parasitol. 119, 249-256 (2002).
7. Pagola, S., Stephens, P. W., Bohle, D. S., Kosar, A. D. & Madsen, S. K. The structure of malaria pigment β-haematin. Nature 404, 307-310 (2000).
8. Egan, T. J. Haemozoin formation. Mol. Biochem. Parasitol. 157, 127-136 (2008).
9. Foley, M. & Tilley, L. Quinoline antimalarials: mechanisms of action and resistance. Int. J. Parasitol. 27, 231-240 (1997).
10. Fitch, C. D. Chloroquine resistance in malaria: a deficiency of chloroquine binding. Proc. Natl Acad. Sci. USA 64, 1181-1187 (1969).
11. Krogstad, D. J. et al. Efflux of chloroquine from Plasmodium falciparum: mechanism of chloroquine resistance. Science 238, 1283-1285 (1987).
12. Fidock, D. A. et al. Mutations in the P. falciparum digestive vacuole transmembrane protein PfCRT and evidence for their role in chloroquine resistance. Mol. Cell 6, 861-871 (2000).
13. Cooper, R. A. et al. Alternative mutations at position 76 of the vacuolar transmembrane protein PfCRT are associated with chloroquine resistance and unique stereospecific quinine and quinidine responses in Plasmodium falciparum. Mol. Pharmacol. 61, 35-42 (2002).
14. Martin, S. K., Oduola, A. M. & Milhous, W. K. Reversal of chloroquine resistance in Plasmodium falciparum by verapamil. Science 235, 899-901 (1987).
15. van Schalkwyk, D. A. & Egan, T. J. Quinoline-resistance reversing agents for the malaria parasite Plasmodium falciparum. Drug Resist. Updat. 9, 211-226 (2006).
16. Kelly, J. X. et al. Design, synthesis, and evaluation of 10-N-substituted acridones as novel chemosensitizers in Plasmodium falciparum. Antimicrob. Agents Chemother. 51, 4133-4140 (2007).
17. Bhattacharjee, A. K., Kyle, D. E. & Vennerstrom, J. L. Structural analysis of chloroquine resistance reversal by imipramine analogs. Antimicrob. Agents Chemother. 45, 2655-2657 (2001).
18. Bhattacharjee, A. K., Kyle, D. E., Vennerstrom, J. L. & Milhous, W. K. A 3D QSAR pharmacophore model and quantum chemical structure - activity analysis of chloroquine(CQ)-resistance reversal. J. Chem. Inf. Comput. Sci. 42, 1212-1220 (2002).
19. Fivelman, Q. L., Adagu, I. S. & Warhurst, D. C. Modified fixed-ratio isobologram method for studying in vitro interactions between atovaquone and proguanil or dihydroartemisinin against drug-resistant strains of Plasmodium falciparum. Antimicrob. Agents Chemother. 48, 4097-4102 (2004).
20. Waller, K. L. et al. Chloroquine resistance modulated in vitro by expression levels of the Plasmodium falciparum chloroquine resistance transporter. J. Biol. Chem. 278, 33593-33601 (2003).
21. Cooper, R. A., Hartwig, C. L. & Ferdig, M. T. pfcrt is more than the Plasmodium falciparum chloroquine resistance gene: a functional and evolutionary perspective. Acta Trop. 94, 170-180 (2005).
22. Cooper, R. A. et al. Mutations in transmembrane domains 1, 4 and 9 of the Plasmodium falciparum chloroquine resistance transporter alter susceptibility to chloroquine, quinine and quinidine. Mol. Microbiol. 63, 270-282 (2007).
23. World Health Organization. Guidelines for the Treatment of Malaria. WHO/HTM/ MAL/2006.1108 (WHO, 2006).
24. Biot, C. & Chibale, K. Novel approaches to antimalarial drug discovery. Infect. Disord. Drug Targets 6, 173-204 (2006).
25. Egan, T. J. & Kaschula, C. H. Strategies to reverse drug resistance in malaria. Curr. Opin. Infect. Dis. 20, 598-604 (2007).
26. Biot, C. et al. Insights into the mechanism of action of ferroquine. Relationship between physicochemical properties and antiplasmodial activity. Mol. Pharm. 2, 185-193 (2005).
27. Burgess, S. J. et al. A chloroquine-like molecule designed to reverse resistance in Plasmodium falciparum. J. Med. Chem. 49, 5623-5625 (2006).
28. Smilkstein, M., Sriwilaijaroen, N., Kelly, J. X., Wilairat, P. & Riscoe, M. Simple and inexpensive fluorescence-based technique for high-throughput antimalarial drug screening. Antimicrob. Agents Chemother. 48, 1803-1806 (2004).